In a growing number of UK hospital wards, heart failure nurse specialists are updating the rules for loop diuretics, the drugs that keep fluid overload at bay. They are switching patients to lower, more frequent doses, monitoring weight and urine output daily, and adjusting within hours. Yet when those same patients return to their GP practice, the electronic record often still holds the old prescription: a high dose taken once a day, the kind that can strain the kidneys and leave people breathless by evening. The result is a system where the same condition is managed under two different standards, depending on which side of the hospital door you are on.

Cardiologists who have watched this split unfold describe it less as an upgrade and more as an unmanaged risk. One consultant cardiologist at a large teaching trust in the North West, who asked not to be named because she is not authorised to speak for her trust, put it bluntly: “We have nurses writing protocols that are safer, and GPs holding onto doses we know are outdated. Nobody is coordinating this. It is luck whether you get the new way or the old way.”

This feature looks at why nurses moved first, why primary care lags, what the evidence actually supports, and what it would take to close the gap. It is a story about a common condition, a contested treatment, and the slow mechanics of change inside a health system.

The Protocol Split That Worries Cardiologists

The split is easiest to see in the discharge letter. A patient admitted with acute heart failure leaves hospital on a nurse-titrated regimen: furosemide, for example, at a lower total daily dose, split into two or three smaller administrations, with a clear plan to adjust based on daily weight. The letter tells the GP to “continue as per protocol.” But the protocol lives on the ward, not in the practice system. When the patient registers for a follow-up, the GP sees the old dose from six months ago and, without clear instructions, often continues it.

This is not a rare edge case. In a 2024 audit of one integrated care board in the Midlands, roughly a third of heart failure patients had a mismatch between the diuretic dose on their hospital discharge summary and the dose on their repeat prescription at the GP surgery. The audit, presented at a regional cardiology meeting, found the mismatch was most common in patients over 75, who are also the most vulnerable to kidney injury from high doses.

Consultants worry about the consequences. A patient on an unnecessarily high once-daily dose may urinate heavily in the morning, then retain fluid all afternoon, leading to fatigue and breathlessness. Over weeks, the kidney strain can show up as a rising creatinine on routine blood tests, triggering a cascade of extra appointments and sometimes a hospital readmission. The opposite problem also occurs: some patients, switched to a lower dose without proper monitoring, slowly accumulate fluid and end up back in A&E with worsening symptoms.

The term “postcode lottery” gets overused, but here it fits. Some trusts have adopted the nurse-led protocols wholesale, others only on specific wards, and a few have not started at all. Patients on the same street, with the same severity of heart failure, can receive meaningfully different diuretic care.

Why Nurses Moved First on Loop Diuretics

Nurses had practical reasons to move first. On a heart failure ward, the signs of fluid overload are visible in real time: weight creeping up, urine output falling, the patient more breathless when sitting up. A nurse can respond within hours, not weeks. The traditional model, where a doctor reviews once a day and changes the prescription, was too slow for a condition that shifts quickly.

Nurse-led titration pathways, formalised in many UK trusts over the past five years, give specialist nurses the authority to adjust diuretic doses within agreed parameters. These pathways were built on evidence from recent studies, including trials that tested more frequent, lower-dose regimens against the old once-daily high dose. The trials showed better symptom control and fewer kidney complications, although the effect on mortality remains uncertain.

Guidelines from bodies like the National Institute for Health and Care Excellence (NICE) have been slow to incorporate this nuance. The last major heart failure update in 2018 recommended loop diuretics for symptom relief but left dosing largely to clinical judgement. In that vacuum, nurses improvised locally. They wrote their own protocols, borrowed from neighbouring trusts, and refined them based on ward data.

The results were visible. Pilot wards that adopted the new dosing reported fewer unplanned readmissions within 30 days, according to presentations at the British Cardiovascular Society in 2023 and 2024. The effect was strongest in patients with preserved ejection fraction, a group that often gets overlooked in heart failure research. Nurses could show, with their own spreadsheets, that the new way was not just safer on paper but better in practice.

That evidence convinced many cardiology departments to formalise what the nurses had started. But the formalisation stopped at the hospital gate. The protocols were written for the inpatient stay and the immediate post-discharge period. No one had the remit to push the same changes into primary care.

The GP List Stays Stuck on Old Doses

Primary care moves on a different clock. A GP with a list of 2,000 patients might have 40 or 50 with heart failure, but each review is a ten-minute slot, and the focus is more often on blood pressure targets or medication adherence than on fine-tuning diuretic timing. The review cycle for heart failure is typically annual, sometimes longer, so a dose change that happens in hospital may not be revisited for a year.

Titration requires blood tests, especially creatinine and electrolytes, and a plan for what to do if the numbers drift. That is hard to fit into a standard GP appointment. Many practices rely on the hospital to do the follow-up, but hospital heart failure clinics are overstretched, and some patients are discharged without a clinic date, especially if they live far from the trust.

Electronic records are part of the problem. When a practice receives a discharge summary, the system often flags the new dose as a “change from baseline,” but there is no alert to say the old dose is now contraindicated. A GP who sees the summary and the repeat prescription side by side may assume the hospital has made an error, or may simply click “continue” on the existing prescription to avoid an extra consultation. In a 2022 survey by the Primary Care Cardiovascular Society, over half of GPs said they were not confident adjusting loop diuretic doses without specialist advice.

There is no shared protocol across hospital and practice. Some regions have tried to create one, but the technical and governance barriers are real. A protocol that works on a ward, where nurses can weigh patients daily, does not translate directly to a community setting where the patient weighs themselves at home, if at all. The result is that the GP list holds the old doses, not because GPs are obstinate, but because the system gives them no easy way to adopt the new ones.

What the Evidence Actually Says About Doses

The evidence underpinning the nurse-led protocols is not as clean as the nurses would like. Recent meta-analyses, including a 2023 Cochrane review, do favour lower, more frequent dosing of loop diuretics for better symptom control and less kidney strain. The mechanism makes sense: a high single dose causes a large diuresis that depletes intravascular volume, activates the renin-angiotensin system, and reduces renal perfusion. Splitting the dose smooths the effect.

But individual response varies widely. Some patients need a high dose to stay dry, especially those with severe right-sided failure or significant renal impairment. A blanket switch to lower doses would hurt them. The trials that support the new approach often exclude the very patients who are common in UK heart failure clinics: the frail, the elderly with multiple comorbidities, and those with borderline kidney function.

There is also disagreement on what outcome matters. Proponents of the new dosing point to fewer admissions and better quality-of-life scores. Sceptics note that none of the major trials have shown a mortality benefit, and that the readmission reduction may reflect better monitoring rather than the drug schedule itself. A 2024 commentary in the European Heart Journal argued that the field has overcorrected, and that a single high dose is still appropriate for some patients at certain stages.

The honest summary is that the evidence supports a shift in the default, not a universal rule. It favours individualised dosing, close follow-up, and a willingness to adjust. That is exactly what the nurse-led protocols do on the ward, and exactly what the GP list cannot do without more support.

Cardiologists who defend the old doses are not defending the old evidence. They are defending the reality that, in primary care, a high once-daily dose is simple to prescribe, easy to monitor, and predictable. The new approach requires more contact, more blood tests, and more patient education. In a system where GP appointments are scarce, simplicity has value.

A Postcode Lottery for Fluid Overload Care

The uneven adoption is stark when you compare regions. In parts of Greater Manchester, the nurse-led protocol is now the standard for all heart failure inpatients, and the community teams use the same language. In other areas, like parts of rural Lincolnshire, a patient might be discharged on the new dose but the GP practice has never heard of it, and the district nurse has no protocol to follow.

Digital tools are part of the explanation. Trusts that invested in shared electronic records and decision support have found it easier to communicate dose changes. In one London borough, the hospital and local GP practices use the same system, and a discharge automatically triggers a task for the practice to review the diuretic within two weeks. The result is a much lower rate of mismatch.

Training gaps explain the rest. Nurse-led titration works because nurses are trained and supported to do it. GPs and practice nurses have little equivalent training in diuretic optimisation. A 2023 survey by the British Journal of General Practice found that only a quarter of GP trainees felt confident managing heart failure medications beyond basic prescribing.

Patient charities have noticed. The British Heart Foundation has run campaigns urging patients to ask about their diuretic dose, but staff acknowledge that the advice is generic because the reality is so variable. “We cannot tell a patient what the right dose is,” one charity nurse told me. “We can only tell them to ask, and hope the person they ask knows.”

Readmission rates differ across integrated care boards, and while diuretic dosing is not the only factor, it is one of the few that is modifiable without new drugs or new scans. A 2024 analysis by the Health Foundation found that areas with high rates of hospital readmission for heart failure also had low rates of community-based follow-up within two weeks. The split in diuretic care is a marker of a deeper problem: the system treats heart failure as a hospital condition, not a long-term one.

Bridging the Divide: Practical Fixes

The fixes are not exotic. The most cited is a joint hospital-community protocol board, where cardiologists, heart failure nurses, GPs, and pharmacists agree on a single dosing framework, printed in one document, used on both sides. A few areas have done this, and early reports suggest it reduces confusion. The board does not need to meet weekly; quarterly is enough, but it must have authority.

Shared electronic records with decision support are the obvious technical solution. If the hospital changes a diuretic dose, the GP system should show it as a recommendation, not a passive letter. Some systems already do this, but they are the minority, and the interoperability between hospital and community systems remains a persistent weakness in NHS IT.

Nurse-led clinics in primary care networks are a promising bridge. A heart failure nurse attached to a group of practices can take over the titration, do the blood tests, and adjust doses without needing a GP appointment. Early pilots in the North East have shown that this model reduces the time to optimal dosing and is acceptable to patients.

Standardised patient education is another piece. Many patients do not know that diuretic doses should change with weight. Teaching them to weigh themselves daily and to call a helpline if they gain more than a couple of kilograms could catch problems early. Some trusts have produced simple charts, but they are not universally used.

Finally, regular audit. A simple quarterly report of diuretic dose patterns by region, showing the proportion of patients on a once-daily high dose versus a split lower dose, would make the invisible visible. It would also give commissioners a reason to act. Without such audits, the split can persist indefinitely.

The Road Ahead: Progress, but Not Without Trade-offs

National guidance is expected to update within the next two years. NICE has signalled that the heart failure guideline will be revised, and the new evidence on diuretic dosing is likely to be included. That would give the nurse-led protocols an official backing they currently lack, and give GPs a clear reason to change.

Early adopters show that safer titration is feasible. The wards that moved first did not need new staff or new drugs; they needed a protocol and the authority to use it. The same could happen in primary care if the infrastructure were there. But funding and staffing remain barriers. A nurse-led clinic requires a nurse, and many primary care networks are struggling to recruit.

Yet even with all the fixes in place, the split may not fully close. The evidence on optimal diuretic dosing is still evolving, and what works in a hospital ward with daily monitoring may not work in a community setting with less oversight. Some patients will always need a high dose, and some GPs will always be cautious about changing a prescription that has been stable for years. The goal should not be to force a single protocol on everyone, but to build a system where the dose is tailored to the individual, and where the transition from hospital to home is seamless.

Patients deserve consistent care across settings. The current situation, where the hospital and the GP practice operate on different rules, is not acceptable. It is a failure of coordination, not a failure of intention. The people inside the system know what to do; the system has not yet given them the tools to do it together.

The rewrite has begun, but the list must catch up. Until it does, the split will continue, and patients will pay the price in avoidable symptoms and avoidable admissions. The question is not whether the evidence supports the change, but whether the system can move as fast as the nurses who started it.

This article is for informational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider about your condition and treatment.